Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in HRR-mutated metastatic castration-sensitive prostate cancer
NL-OMON56019Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Niraparib + abiraterone acetate + prednisone with Placebo + abiraterone acetate + prednisone (2 arms). Primary endpoint: Radiographic progression-free survival. Started Dec 2020; status: completed.
02
Drugs
niraparibabirateroneprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON56019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56019.